Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AMAG dives on FDA notice of deficiencies with Feraheme sNDA

This article was originally published in Scrip

Executive Summary

Shares of AMAG took a 16% dive on 25 September after the company disclosed the US FDA had identified deficiencies that preclude discussion of labeling and postmarketing requirements and commitments for the supplemental new drug application (sNDA) for Feraheme (ferumoxytol) for broader use in treating iron deficiency anemia (IDA) in adults with chronic kidney disease (CKD) who have failed or could not use oral iron.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts